Want to read more?
At the start of the pandemic in March we took the decision to make online access to our news free of charge by taking down our paywall. At a time where accurate information about Covid-19 was vital to our community, this was the right decision – even though it meant a drop in our income. In order to help safeguard the future of our journalism, the time has now come to reinstate our paywall, However,
rest assured that access to all Covid related news will still remain free.
To access all other news will require a subscription, as it did pre-pandemic. The good news is that for the whole of December we will be running a special discounted offer to get 3 months access for the price of one month. Thank you for supporting us during this incredibly challenging time.
Key Insights from The IMPACT SERIES: Disrupting Petcare 3min read
Alex Khourdaji – Analyst
As brands seek to maintain a competitive edge, many have expanded their position into the petcare segment. Identical to products designed for humans, pet CBD products come in various flavours and strengths and also formats for certain pets.
Prohibition Partners estimates that the global market for pet CBD reached an estimated
US$214.44 million in 2020, with the majority of sales occurring in North America followed by sales in Europe. By 2024, Prohibition Partners projects global sales of CBD petcare products to reach
US$424.38 million.
As consumers seek new ways to enrich their quality of life using CBD products, pet owners are using pet CBD products to ensure their dogs, cats, and horses are receiving comprehensive care using enriched foods and supplements. The increase in pet CBD product sales directly correlates with the growing trend of pet humanisation. Pet humanisation
NPB Approval gives Aivlosin WSG the broadest label indication of any product for the control of swine respiratory disease.
Feb 02, 2021
In January 2021, the FDA’s Center for Veterinary Medicine, as well as the Veterinary Drugs Directorate of Health Canada, added
Mycoplasma hyopneumoniae to the approved label indications for Aivlosin (
tylvalosin) Water Soluble Granules (WSG).
“This approval gives Aivlosin WSG the broadest label indication of any product for the control of swine respiratory disease (SRD),” said Dr. Chad Smith, U.S. technical service veterinarian for Pharmgate. “
M. hyo is a primary pathogen in swine respiratory disease complexes and plays an important role in facilitating the entry of bacterial and viral pathogens. Aivlosin WSG is competitive economically compared to other protocols on a per-pig basis. Veterinarians and producers can be confident they are making a responsible antibiotic choice to control SRD.”
The Veterinary Medicines Directorate and Health Canada's Veterinary Drugs Directorate (VDD) have been discussing the opportunity to conduct simultaneous.